Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Recruiting · NCT06657209 · Registry updated 2026-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide | Insulin Resistance, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose intolerance, glucose metabolism disease, hyperglycemia, hyperinsulinism, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 4 | 2026-04-20 | NCT06657209 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Stanford University | 620 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Stanford University | Palo Alto | United States | 161 |
| Stanford University, Clinical and Translational Research Unit (CTRU) | Stanford | United States | 1 |